PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.\', \'Division of Neurological Sciences, Vetsuisse Faculty, University of Bern, Bern, Switzerland.\', \'Department of Membrane Enzymology at the Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, The Netherlands.\', \'Linkster Therapeutics AG, Zurich, Switzerland.\', \'Department of Structural Biology at the Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Groningen, The Netherlands.\', \'Institute of Virology and Immunology, Bern & Mittelhäusern, Switzerland.\', \'Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.\', \'Interfaculty Bioinformatics Unit and Swiss, Institute of Bioinformatics, University of Bern, Bern, Switzerland.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.15252/embr.202154199
?:hasPublicationType
?:journal
  • EMBO reports
is ?:pmid of
?:pmid
?:pmid
  • 35253970
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 4.724
?:rankingScore_hIndex
  • 158
?:title
  • Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35253970>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35253970>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all